NextGen Sciences
will develop validated protein biomarker assays to be used in
Takeda Pharmaceutical’s preclinical and clinical studies, supporting its drive toward personalized medicine.
The biomarker assays will be designed to target specific protein isoforms found in the liver and muscle of multiple species for use in preclinical studies. The assays will also be validated for use in clinical studies. NextGen Sciences reports that its Multiple Reaction Monitoring protein assay platform is useful for studies of this kind, which involve multiple isoforms and multiple species.